Global Axial Spondyloarthritis (axSpA) Market Insights Forecasts to 2030
- The Global Axial Spondyloarthritis (axSpA) Market Size was valued at USD 5.2 Billion in 2022.
- The Market is Growing at a CAGR of 6.86% from 2022 to 2032.
- The worldwide Axial Spondyloarthritis (axSpA) Market size is expected to reach USD 10.1 Billion by 2032.
- Asia Pacific is expected To Grow the fastest during the forecast period.
Get more details on this report -
The Global Axial Spondyloarthritis (axSpA) Market Size is expected to reach USD 10.1 billion by 2032, at a CAGR of 6.86% during the forecast period 2022 to 2032. However, with continued advancements in research and development, increasing awareness, and improving access to treatment, the market is expected to grow over the long term.
A group of chronic inflammatory autoimmune diseases known as spondylarthritis (SpA) share several clinical and genetic characteristics. Spondylarthritis, a type of arthritis, affects the spine's joints as well as, occasionally, the arms and legs. Involvement of the axial skeleton (sacroiliac joints and spine), a particular type of peripheral joint involvement (typically asymmetric monoarthritis or Oligoarthritis primarily affecting the joints of the lower extremities), the presence of enthesitis and dactylitis, and frequent extraarticular manifestation are among these features. Nonsteroidal anti-inflammatory medicines (NSAIDs) are the first-line therapy for AxSpA in terms of treatment. The application of biologics which includes tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors in individuals who do not react to NSAIDs may be more aggressive. At this point, TNF inhibitors like adalimumab, etanercept, and infliximab rule the market for AxSpA. The market is anticipated to become more competitive with the approval of novel biologics such as secukinumab, ixekizumab, and upadacitinib.
This research report categorizes the global axial spondyloarthritis (axSpA) market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global axial spondyloarthritis (axSpA) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global axial spondyloarthritis (axSpA) market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Axial Spondyloarthritis (axSpA) Market Report Coverage
|Market Size in 2021:||USD 5.2 Billion|
|Forecast Period 2022-2032 CAGR:||6.86%|
|2032 Value Projection:||USD 10.1 Billion|
|Historical Data for:||2020-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||130|
|Segments covered:||By Types, By Drug Class, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Johnson & Johnson, UCB, Amgen, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Kyowa Kirin, AbbVie, Acelyrin, Pfizer, Reckitt Benckiser Group plc, Sun Pharmaceutical Industries Ltd|
|Pitfalls & Challenges:||COVID-19 has the potential to impact the global market|
Get more details on this report -
AxSpA is becoming more common globally, which is creating a larger patient population. AxSpA is thought to affect adults worldwide, with some locations having higher prevalence rates than others. Also, AxSpA is becoming more widely known among patients and healthcare professionals, leading to earlier diagnosis and treatment, this is expected to increase the demand for effective therapies and drive market growth. The advancements in diagnostic techniques, such as magnetic resonance imaging (MRI), have improved the accuracy of AxSpA diagnosis, leading to earlier treatment and better outcomes. Moreover, the development of new and effective therapies, such as biologics and biosimilars, has expanded the treatment options available to patients with AxSpA and is expected to increase patient access to treatment and drive market growth. In addition, increasing healthcare spending in both developed and developing countries and favorable Reimbursement Policies is expected to increase patient access to treatment and drive market growth. Overall, the global AxSpA market is expected to grow significantly in the upcoming years, driven by these and other factors.
The factors that may limit the growth of the global AxSpA market include the high cost of biologics, such as TNF inhibitors, which can be a significant barrier to treatment access for some patients, especially in low- and middle-income countries. Also, despite increasing awareness in many patients and healthcare professionals still have limited knowledge about AxSpA, leading to underdiagnosis and undertreatment. Moreover, the expiry of patents for some biologics is expected to increase competition and drive down prices, but it may also lead to a decrease in revenues for companies that hold these patents. Stringent regulatory requirements for drug approval and reimbursement can delay market entry for new therapies and limit patient access to treatment.
In 2022, ankylosing spondylitis is driving the market with the largest market share over the forecast period.
Based on the types, global axial spondyloarthritis (axSpA) is classified into ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Among these, the ankylosing spondylitis segment is the major revenue-contributing segment. AS is a type of AxSpA that affects the spine and sacroiliac joints and is characterized by inflammation and bone growth, which can lead to chronic pain and stiffness. It is estimated that approximately 90% of AxSpA cases are classified as ankylosing spondylitis.
In 2022, the anti-inflammatory drugs segment is dominating the market over the forecast period.
Based on the drug class, global axial spondyloarthritis (axSpA) is bifurcated into non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, anti-rheumatic drugs, & others. Among these, the segment non-steroidal anti-inflammatory drugs (NSAID) is dominating the market during the forecast period owing to the nonsteroidal anti-inflammatory medicines (NSAIDs) are very effective in treating the primary symptoms and signs of axSpA (pain and stiffness), and they may also have the ability to slow the progression of structural spine deterioration. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (Naprosyn) and indomethacin (Indocin and Tivorbex), are the medications preferred by doctors in axial spondyloarthritis.
Regional Segment Analysis of the Axial Spondyloarthritis (axSpA) Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is influencing the market with the largest market share over the forecast period
Get more details on this report -
North America is anticipated to account for a sizeable portion of the global market for axial spondyloarthritis, due to the rising prevalence, more awareness, and improved diagnosis in this region, North America is anticipated to account for a sizeable portion of the global market for axial spondyloarthritis. Moreover, axial spondyloarthritis affects the younger spondyloarthritis patient population, with an average age of symptom onset of 28 years. Additionally, the prevalence of ankylosing spondylitis ranged from 9 to 30 per 10,000 people, which is lower than previous estimates, according to the study Investigating Diagnosis, Treatment, and Burden of Disease in Patients with Ankylosing Spondylitis in Central Eastern Europe and the United States: A Real-World Study, which was published in July 2021. The favorable reimbursement policies in the US and Canada have also contributed to the growth of the AxSpA market. The availability of insurance coverage for expensive biologic drugs has made these treatments more accessible to patients, leading to increased demand.
Asia Pacific is expected to register significant growth over the forecast period due to the elderly population has significantly increased in nations like China and India. Additionally, the presence of generic drug manufacturers and the expansion of healthcare facilities in the area are key factors in the region’s revenue growth.
The report offers the appropriate analysis of the key organizations/companies involved within the global axial spondyloarthritis (axSpA) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Johnson & Johnson
- Novartis Pharmaceuticals Corporation
- Eli Lilly and Company
- Kyowa Kirin
- Reckitt Benckiser Group plc
- Sun Pharmaceutical Industries Ltd
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In July 2022, The European Commission authorized RINVOQ (upadacitinib) as an oral medication for individuals with active axial spondyloarthritis that is non-radiographic.
- In April 2022, Axial Spondyloarthritis (axSpA) patients can now receive assistance thanks to cooperation between Ampersand Health and UCB. Project Nightingale, an ongoing investigation led by Bath's Royal National Hospital for Rheumatic Diseases (RNHRD), will get back from the two businesses. The goal of the study is to help people with axSpA better manage their symptoms and overall quality of life.
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the global axial spondyloarthritis (axSpA) market based on the below-mentioned segments:
Global Axial Spondyloarthritis (axSpA) Market, By Type
- Ankylosing spondylitis (AS)
- Non-radiographic axial spondyloarthritis (nr-axSpA)
Global Axial Spondyloarthritis (axSpA) Market, By Drug Class
- Non-steroidal anti-inflammatory drugs (NSAID)
- Anti-rheumatic drugs
Axial Spondyloarthritis (axSpA) Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?